| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vivo |
Dogs treated with 5 mg/kg/day of butamoren mesylate gained statistically significant weight and had higher levels of GH and IGF-1 in their serum. On research days 7 or 15, there was no discernible rise in CSF IGF-1 or GH levels due to imitabromen mesylate [1]. Ibutamoren mesylate (50 μg, ip) could not activate these neurons in animals treated with GH prior to treatment. GH and octreotide do not block Ibutamoren mesylate's stimulation of arcuate neurons in gene-knockout mice [2]. Significant increases in GH and IGF-I levels were linked to long-term oral administration of butamoren mesylate, and these effects persisted throughout treatment. After administering ibutamoren mesylate, the GH profile exhibits sporadic elevations over controls [3]. Following oral treatment, ibutamoren mesylate dramatically raises peak GH concentrations. When taken orally or intravenously, ibutamoren mesylate is a strong GH secretagogue that can raise GH levels quickly, significantly, and persistently [4].
|
|---|---|
| References |
[1]. Prahalada S, et al. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7.
[2]. Zheng H, et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrinol. 1997 Oct;11(11):1709-17. [3]. Hickey GJ, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997 Feb;152(2):183-92. [4]. Jacks T, et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology. 1996 Dec;137(12):5284-9 |
| Molecular Formula |
C28H40N4O8S2
|
|---|---|
| Molecular Weight |
624.77
|
| CAS # |
159752-10-0
|
| SMILES |
S(C([H])([H])[H])(N1C2=C([H])C([H])=C([H])C([H])=C2C2(C1([H])[H])C([H])([H])C([H])([H])N(C([C@@]([H])(C([H])([H])OC([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])C(C(C([H])([H])[H])(C([H])([H])[H])N([H])[H])=O)=O)C([H])([H])C2([H])[H])(=O)=O.S(C([H])([H])[H])(=O)(=O)O[H]
|
| Solubility (In Vitro) |
H2O: ≥ 50 mg/mL (80.03 mM)
DMSO: 50 mg/mL (80.03 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (160.06 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL | |
| 5 mM | 0.3201 mL | 1.6006 mL | 3.2012 mL | |
| 10 mM | 0.1601 mL | 0.8003 mL | 1.6006 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
